

OTUD5/DUBA Rabbit pAb

OTUD5/DUBA Rabbit pAb

Catalog # AP56745

Product Information

Application	IHC-P, IHC-F, IF
Primary Accession	Q96G74
Reactivity	Human
Predicted	Rat, Mouse, Rabbit, Chicken
Host	Rabbit
Clonality	Polyclonal
Calculated MW	60626
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human OTUD5/DUBA
Epitope Specificity	501-571/571
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	This gene encodes a member of the OTU (ovarian tumor) domain-containing cysteine protease superfamily. The OTU domain confers deubiquitinase activity and the encoded protein has been shown to suppress the type I interferon-dependent innate immune response by cleaving the polyubiquitin chain from an essential type I interferon adaptor protein. Cleavage results in disassociation of the adaptor protein from a downstream signaling complex and disruption of the type I interferon signaling cascade. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Oct 2008]

Additional Information

Gene ID	55593
Other Names	OTU domain-containing protein 5, 3.4.19.12, Deubiquitinating enzyme A, DUBA, OTUD5 (HGNC:25402)
Dilution	IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.


Protein Information

Name	OTUD5 (HGNC:25402)
Function	Deubiquitinating enzyme that functions as a negative regulator of the innate immune system (PubMed: 17991829 , PubMed: 22245969 , PubMed: 23827681 , PubMed: 33523931). Has peptidase activity towards 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains (PubMed: 22245969). Can also cleave 'Lys-11'-linked ubiquitin chains (in vitro) (PubMed: 22245969). Acts via TRAF3 deubiquitination and subsequent suppression of type I interferon (IFN) production (PubMed: 17991829). Controls neuroectodermal differentiation through cleaving 'Lys-48'-linked ubiquitin chains to counteract degradation of select chromatin regulators such as ARID1A, HDAC2 and HCF1 (PubMed: 33523931). Acts as a positive regulator of mTORC1 and mTORC2 signaling following phosphorylation by MTOR: acts by mediating deubiquitination of BTRC, leading to its stability (PubMed: 33110214).
Cellular Location	Nucleus.
Tissue Location	Expressed in various tissues, including the liver and placenta, as well as in peripheral blood leukocytes

Background

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Images



Tissue/cell: human cervical cancer; 4%
 Paraformaldehyde-fixed and paraffin-embedded;
 Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min;
 Incubation: Anti-OTUD5 Polyclonal Antibody, Unconjugated(AP56745) 1:500, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.